<< Read Full Article
<< Read Full Article
Change in Ratings
American Tower (AMT Quote) upgraded at Goldman Sachs to Buy from Neutral based on defensive characteristics in market where credit availability is expected to remain limited. Tower sector has underperformed recently due to leverage characteristics and perceived risks around ownership concentrations. Price target at $53.
Boston Scientific (BSX Quote) downgraded at Merrill to Underperform. $12 price target. Company will likely not gain back market share as quickly as expected in 2009. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,285.97 | 1,091.93 | 2,172.99 | 33.92 |
Oil *
75.40
|
|
DOWN
104.14
|
DOWN
11.32
|
DOWN
16.62
|
DOWN
0.56
|
10 Yr
3.39%
SPDR Gold
110.95
|
|
-1.00%
|
-1.03%
|
-0.76%
|
-1.62%
|
Data delayed 20 minutes |
Connect with TheStreet